Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Neil P. Desai"'
Autor:
Craig E. Grossman, MD, PhD, MSCE, Michael R. Folkert, MD, Stephanie Lobaugh, MS, Neil B. Desai, MD, MHS, Marisa A. Kollmeier, MD, Daniel Gorovets, MD, Sean M. McBride, MD, MPH, Robert D. Timmerman, MD, Zhigang Zhang, PhD, Michael J. Zelefsky, MD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 4, Pp 101070- (2023)
Purpose: Although hydrogel spacer placement (HSP) minimizes rectal dose during prostate cancer radiation therapy, its potential benefit for modulating rectal toxicity could depend on the achieved prostate-rectal separation. We therefore developed a q
Externí odkaz:
https://doaj.org/article/3268af5e2160445b81ff50e7833a90da
Autor:
Steven K. Montalvo, Boyu Meng, Mu-Han Lin, Chunjoo Park, Neil B. Desai, Raquibul Hannan, Aurelie Garant
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Adaptive radiotherapy has the potential to reduce margins, improve target coverage, and decrease toxicity to organs at risk (OARs) by optimizing radiation delivery to daily anatomic changes. Salvage for locally recurrent prostate cancer after definit
Externí odkaz:
https://doaj.org/article/264d779aa41b48f19a74a4559c13ea1e
Autor:
Lily Chen, Bhavani S. Gannavarapu, Neil B. Desai, Michael R. Folkert, Michael Dohopolski, Ang Gao, Chul Ahn, Jeffrey Cadeddu, Aditya Bagrodia, Solomon Woldu, Ganesh V. Raj, Claus Roehrborn, Yair Lotan, Robert D. Timmerman, Aurelie Garant, Raquibul Hannan
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposeStereotactic ablative radiation (SAbR) has been increasingly used in prostate cancer (PCa) given its convenience and cost efficacy. Optimal doses remain poorly defined with limited prospective comparative trials and long-term safety/efficacy d
Externí odkaz:
https://doaj.org/article/1785e62e49d146eb88afc56fce6ace43
Autor:
Mark F. McLaughlin, MD, PhD, Michael R. Folkert, MD, PhD, Robert D. Timmerman, MD, Raquibul Hannan, MD, Aurelie Garant, MD, Steven J. Hudak, MD, Daniel N. Costa, MD, Neil B. Desai, MD
Publikováno v:
Advances in Radiation Oncology, Vol 6, Iss 4, Pp 100713- (2021)
Externí odkaz:
https://doaj.org/article/2842b0c1fce24656bb1ac0f32e752f87
Autor:
Roche Kapoor, Matthew P. Deek, Riley McIntyre, Natasha Raman, Megan Kummerlowe, Iyah Chen, Matt Gaver, Hao Wang, Sam Denmeade, Tamara Lotan, Channing Paller, Mark Markowski, Michael Carducci, Mario Eisenberger, Tomasz M. Beer, Daniel Y. Song, Theodore L. DeWeese, Jason W. Hearn, Stephen Greco, Curtiland DeVille, Neil B. Desai, Elisabeth I. Heath, Stanley Liauw, Daniel E. Spratt, Arthur Y. Hung, Emmanuel S. Antonarakis, Phuoc T. Tran
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background In men with a rising PSA following radical prostatectomy, salvage radiation therapy (SRT) offers a second chance for cure. Hormonal therapy can be combined with SRT in order to increase prostate tumor control, albeit with associat
Externí odkaz:
https://doaj.org/article/2eb48a9b5d9f4772a8b098572c4cd10f
Autor:
Collin Gilbreath, Shihong Ma, Lan Yu, Rajni Sonavane, Carlos M. Roggero, Anvita Devineni, Ryan Mauck, Neil B. Desai, Aditya Bagrodia, Ralf Kittler, Ganesh V. Raj, Yi Yin
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100898- (2021)
The study of DNA damage repair response (DDR) in prostate cancer is restricted by the limited number of prostate cancer cell lines and lack of surrogates for heterogeneity in clinical samples. Here, we sought to leverage our experience with patient d
Externí odkaz:
https://doaj.org/article/81556393fb8f47888a4c4ffdabdcfa43
Autor:
Osama Mohamad, Alberto Diaz de Leon, Samuel Schroeder, Andrew Leiker, Alana Christie, Elizabeth Zhang-Velten, Lakshya Trivedi, Saad Khan, Neil B Desai, Aaron Laine, Kevin Albuquerque, Puneeth Iyengar, Yull Arriaga, Kevin Courtney, David E. Gerber, Hans Hammers, Hak Choy, Robert Timmerman, James Brugarolas, Raquibul Hannan
Publikováno v:
OncoImmunology, Vol 7, Iss 7 (2018)
Integration of hypofractionated body radiotherapy (H-RT) into immune checkpoint inhibitor (ICI) therapy may be a promising strategy to improve the outcomes of ICIs, although sufficient data is lacking regarding the safety and efficacy of this regimen
Externí odkaz:
https://doaj.org/article/1b440311a27840808257a962dd3e4584
Autor:
Katherine E. Harris, Berta Grigorian, Anita N. Schmid, Rashmi Chugh, Andrew J. Wagner, Shihe Hou, Neil P. Desai, Mark A. Dickson, Kristen N. Ganjoo, Vinod Ravi, Brian A. Van Tine, Lee D. Cranmer, Jason L. Hornick, Richard F. Riedel, Erlinda M. Gordon, Heng Du, David J. Kwiatkowski
Publikováno v:
Journal of Clinical Oncology. 39:3660-3670
PURPOSE Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease, investig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf81d53afe8152f908842cfd4492123d
https://doi.org/10.1200/jco.21.01728
https://doi.org/10.1200/jco.21.01728
Publikováno v:
Molecular Cancer Therapeutics. 20:P138-P138
Background: TSC1, TSC2, and PTEN genes are tumor suppressors in the mTOR pathway and can be inactivated or deleted across many cancers (Kwiatkowski, Clin Cancer Res 2016). The mTORC1 pathway is frequently activated in cancer and causes phosphorylatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b78cba63036eed19834907e40c6e2ec4
https://doi.org/10.1158/1535-7163.targ-21-p138
https://doi.org/10.1158/1535-7163.targ-21-p138
Publikováno v:
Molecular Cancer Research. 18:B08-B08
Background: mTOR pathway is a key regulator of cell survival and proliferation and has been implicated in various indications, including oncology, hematology, and cardiovascular, metabolic, and central nervous system diseases. ABI-009, a novel mTOR i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d15a9bb0160bed16adfbcb862c45fa78
https://doi.org/10.1158/1557-3125.pi3k-mtor18-b08
https://doi.org/10.1158/1557-3125.pi3k-mtor18-b08